Modus Therapeutics' Convertible Note Round

Modus Therapeutics raised a round of funding on July 13, 2018.

Modus Therapeutics, fka Dilaforette, is a clinical-stage drug development company developing new pharmaceutical therapies to restore impaired blood flow and oxygen transport in rare diseases with larg…

Articles about Modus Therapeutics' Convertible Note Round: